- Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
- MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates
- Total potential deal value of up to $586 million, plus royalties on commercial sales
AMSTERDAM, NETHERLANDS, February 3rd, 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces it has entered into a technology agreement with MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads (SYNtecan E™, SYNeamicin D™ and SYNeamicin G™), each designed to enable ADCs with best-in-class efficacy and tolerability. These will be combined with MacroGenics’ proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs.
Under the terms of the agreement, Synaffix will be eligible to receive up to $586 million in payments spanning upfront and milestone payments across three programs plus royalties on commercial sales. The license rights of MacroGenics for each program will be designated as exclusive or non-exclusive to each program’s antibody target (or to the combination of two targets, if bispecific). The first program will commence at signature, with the option to expand the collaboration to a further two programs by March 2023.
MacroGenics will be responsible for research, development, manufacturing and commercialization of the ADCs. At the same time, Synaffix will support MacroGenics’ research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect™ and HydraSpace™ technologies and the toxSYN™ linker-payloads.
Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics, commented:
“We are delighted to be working with Synaffix to produce next generation ADCs with potentially superior therapeutic properties. The ability to obtain all essential ADC technologies from Synaffix, and easily and rapidly combine those with our antibody-based molecules, will enable us to expand our existing portfolio of ADC product candidates and further strengthen our position in the growing ADC field.”
Peter van de Sande, Chief Executive Officer of Synaffix, said:
“The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs. We are pleased to further expand the use of our technology with another leading biotech company that has deep product development capabilities and a long-term commitment to delivering novel therapies for the treatment of cancer.”
